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Cardamonin attenuates hyperalgesia and allodynia in a mouse model of chronic 
constriction injury-induced neuropathic pain: possible involvement of the opioid system 
ABSTRACT 
Neuropathic pain arises from the injury of nervous system. The condition is extremely 
difficult to be treated due to the ineffectiveness and presence of various adverse effects of the 
currently available drugs. In the present study, we investigated the antiallodynic and 
antihyperlagesic properties of cardamonin, a naturally occurring chalcone in chronic 
constriction injury (CCI)-induced neuropathic pain mice model. Our findings showed that 
single and repeated dose of intra-peritoneal administration of cardamonin (3, 10, 30 mg/kg) 
significantly inhibited (P<0.001) the chronic constriction injury-induced neuropathic pain 
using the Hargreaves plantar test, Randall-Selitto analgesiometer test, dynamic plantar 
anesthesiometer test and the cold plate test in comparison with the positive control drug used 
(amitriptyline hydrochloride, 20 mg/kg, i.p.). Pre-treatment with naloxone hydrochloride (1 
mg/kg, i.p.) and naloxone methiodide (1 mg/kg, s.c) significantly reversed the antiallodynic 
and antihyperalgesic effects of cardamonin in dynamic plantar anesthesiometer test and 
Hargreaves plantar test, respectively. In conclusion, the current findings demonstrated novel 
antiallodynic and antihyperalgesic effects of cardamonin through the activation of the 
opioidergic system both peripherally and centrally and may prove to be a potent lead 
compound for the development of neuropathic pain drugs in the future. 
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